Precirix

Precirix

Biotechnology Research

Precision radiopharmaceuticals

About us

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Brussels
Type
Privately Held
Founded
2014
Specialties
Biotechnologies, Targeted Radionuclide Therapy, Oncology, Camel derived antibodies, and Radiopharmaceuticals

Locations

Employees at Precirix

Updates

Similar pages

Funding